Progress in the Mechanism and Clinical Research of Roxadustat in the Treatment of Renal Anemia

Anemia is a common complication of chronic kidney disease(CKD).Poor control seriously affects patients’quality of life and increases cardiovascular risk.Currently commonly used drugs for the treatment of renal anemia are erythropoietin and iron,but lead to an increased risk of hypertension,oxidative stress and cardiovascular disease,allergic reactions.Roxadustat is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitorfor the treatment of renal anemia,inhibiting hypoxia-inducible factors Ubiquitination degradation,maintenance of hypoxia-inducible factor stability,promotion of erythropoietin/erythropoietin receptor expression,improve iron absorption,utilization and transport,Comprehensive regulation of erythropoiesis.This article reviews the mechanism and clinical research progress of rosastatin in the treatment of renal anemia.